Curis

- NASDAQ:CRIS
Last Updated 2024-03-26
  • Curis develops Erivedge, a capsule manufactured for the treatment of adults with skin cancer.
  • Locations

    • Cambridge MA
  • Total Funding (USD)

    8.0 million
  • Industries

    Real Estate, Mobile Apps, Cyber Security
  • Security

    Type: ORD
    CUSIP: 231269200
    ISIN: US2312692005
Filter date
All
Bookmark Created by Last updated
There were no results found.
Filter date
All
Article Author Published
There were no results found.

Request a demo to view additional historical data, and much more.